McKesson Corporation (MCK) Earnings Call Transcripts

McKesson Corporation's Latest Earnings Call - September 14, 2026

In the Q1 fiscal year 2027 earnings call held on September 14, 2026, McKesson Corporation reported strong performance across its segments, leading to a raised EPS guidance of $44.20 to $45, reflecting a growth of approximately 13% to 15%. The company highlighted double-digit growth in three of its four reportable segments, particularly in North America Pharmaceuticals, which saw a 19% increase in operating profit. Management expressed confidence in sustaining momentum and indicated a strategic acquisition of Precision Medicine Group (PMG) to enhance its oncology capabilities, which is expected to be accretive to earnings.

Reported metrics

Guidance from management

McKesson maintained a positive outlook for the remainder of the fiscal year, projecting continued growth across its segments and emphasizing investments in technology and business growth. The company expects to deliver value for shareholders while building for the future.

What management said

Well, I just want to thank you for hosting us this morning. We appreciate the opportunity to share a little bit about the McKesson strategy and recent performance, and we thank you all for being here early on a Monday morning. I appreciate your interest in McKesson.

We think there's a working model that's out there that's already been endorsed and developed. Now we will advocate as we always do on behalf of the community practitioners, whether it's pharmacies or oncologists or anyone else based in the community because that's going to be an important part to solving the macro health care challenges in this country.

What analysts pressed on

Analysts expressed concerns regarding the sustainability of growth in the oncology segment amid evolving reimbursement landscapes and regulatory changes. There were also inquiries about the potential impact of contract renewals with major partners like CVS.

Main topics on the call

• Revenue Growth Across Segments — McKesson experienced double-digit growth in three out of four segments, with North America Pharmaceuticals leading at a 19% increase in operating profit. CEO Brian Tyler stated, "We are pleased with our business performa...
• Raised EPS Guidance — The company raised its EPS guidance by $0.40, now projecting a range of $44.20 to $45 for the fiscal year, which translates to a growth of approximately 13% to 15%. CFO Kenny Cheung noted, "We did raise for the full year...
• Acquisition of Precision Medicine Group — McKesson announced the acquisition of PMG, which is expected to enhance its oncology services and provide a strategic fit with its existing capabilities. Tyler emphasized that PMG "fits both the focus on oncology through...
• Concerns Over Contract Renewals — Management addressed inquiries regarding contract renewals, particularly with CVS, stating they are pleased with the partnership and have a good track record of renewing contracts. Tyler mentioned, "We're very pleased to...

Read the full McKesson Corporation transcript (September 14, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 68 McKesson Corporation earnings call transcripts on record, spanning January 14, 2020 to September 14, 2026. Based on this history, McKesson Corporation reports quarterly. The most recent call on file is dated September 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MCK

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

68

First call

January 14, 2020

Most recent

September 14, 2026

Reporting cadence

quarterly